Rachel Haurwitz, Caribou Biosciences CEO
Caribou’s off-the-shelf CAR-T therapy shows hints of durability in early cut of data
Caribou Biosciences shared an early cut of data Thursday afternoon that suggests its off-the shelf CAR-T therapy for patients with B …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
